Resistin is an indicator of the metabolic syndrome according to five different definitions in the Finnish health 2000 survey

Metabolic Syndrome and Related Disorders

Volumn 9, Issue 3, 2011, Pages 203-210

  Malo, Elina ^a   Ukkola, Olavi ^a   Jokela, Maarit ^a   Moilanen, Leena ^b   Kähönen, Mika ^c   Nieminen, Markku S ^d   Salomaa, Veikko ^e   Jula, Antti ^e   Kesäniemi, Y Antero ^a  

^a UNIVERSITY OF OULU   (Finland)

^b KUOPIO UNIVERSITY HOSPITAL   (Finland)

^c TAMPERE UNIVERSITY HOSPITAL   (Finland)

^d UNIVERSITY OF HELSINKI   (Finland)

^e NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RESISTIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGE; AGED; ARTICLE; ASSAY; BODY HEIGHT; BODY MASS; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CLINICAL ASSESSMENT TOOL; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; FEMALE; FINLAND; GENDER; HEALTH SURVEY; HOMEOSTASIS MODEL ASSESSMENT OF INSULIN RESISTANCE; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; MEDICAL EXAMINATION; METABOLIC SYNDROME X; PREDICTOR VARIABLE; PREVALENCE; PRIORITY JOURNAL; QUANTITATIVE INSULIN SENSITIVITY CHECK INDEX; SYSTOLIC BLOOD PRESSURE; WAIST CIRCUMFERENCE;

AGED; COHORT STUDIES; CROSS-SECTIONAL STUDIES; DIAGNOSTIC TECHNIQUES, ENDOCRINE; FEMALE; FINLAND; HEALTH STATUS INDICATORS; HEALTH SURVEYS; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PREVALENCE; RESISTIN; RISK FACTORS;

EID: 79957667032     PISSN: 15404196     EISSN: 15578518     Source Type: Journal    
DOI: 10.1089/met.2010.0106     Document Type: Article

References (34)

1. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005;365:1415-28. (Pubitemid 40523737)
2. Filkova M, Haluzik M, Gay S, Senolt L. The role of resistin as a regulator of inflammation: Implications for various human pathologies. Clin Immunol 2009;133:157-170.
3. Tilg H, Moschen AR. Adipocytokines: Mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 2006;6:772-783. (Pubitemid 44453463)
4. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS, Lazar MA. The hormone resistin links obesity to diabetes. Nature 2001;409:307-312. (Pubitemid 32151228)
5. Vozarova de Courten B, Degawa-Yamauchi M, Considine RV, Tataranni PA. High serum resistin is associated with an increase in adiposity but not a worsening of insulin resistance in Pima Indians. Diabetes 2004;53:1279-1284. (Pubitemid 38569014)
6. Degawa-Yamauchi M, Bovenkerk JE, Juliar BE, Watson W, Kerr K, Jones R, Zhu Q, Considine RV. Serum resistin (FIZZ3) protein is increased in obese humans. J Clin Endocrinol Metab 2003;88:5452-5455. (Pubitemid 37452753)
7. McTernan CL, McTernan PG, Harte AL, Levick PL, Barnett AH, Kumar S. Resistin, central obesity, and type 2 diabetes. Lancet 2002;359:46-47. (Pubitemid 34119198)
8. Fehmann HC, Heyn J. Plasma resistin levels in patients with type 1 and type 2 diabetes mellitus and in healthy controls. Horm Metab Res 2002;34:671-673. (Pubitemid 36398705)
9. Lee JH, Chan JL, Yiannakouris N, Kontogianni M, Estrada E, Seip R, Orlova C, Mantzoros CS. Circulating resistin levels are not associated with obesity or insulin resistance in humans and are not regulated by fasting or leptin administration: Cross-sectional and interventional studies in normal, insulin-resistant, and diabetic subjects. J Clin Endocrinol Metab 2003;88:4848-4856. (Pubitemid 37357535)
10. Chen CC, Li TC, Li CI, Liu CS, Wang HJ, Lin CC. Serum resistin level among healthy subjects: Relationship to anthropometric and metabolic parameters. Metabolism 2005;54: 471-475.
11. Bokarewa M, Nagaev I, Dahlberg L, Smith U, Tarkowski A. Resistin, an adipokine with potent proinflammatory properties. J Immunol 2005;174:5789-5795. (Pubitemid 40593223)
12. Lehrke M, Reilly MP, Millington SC, Iqbal N, Rader DJ, Lazar MA. An inflammatory cascade leading to hyperresistinemia in humans. PLoS Med 2004;1:e45.
13. Senolt L, Housa D, Vernerova Z, Jirasek T, Svobodova R, Veigl D, Anderlova K, Muller-Ladner U, Pavelka K, Haluzik M. Resistin in rheumatoid arthritis synovial tissue, synovial fluid and serum. Ann Rheum Dis 2007;66:458-463. (Pubitemid 46580464)
14. Qatanani M, Szwergold NR, Greaves DR, Ahima RS, Lazar MA. Macrophage-derived human resistin exacerbates adipose tissue inflammation and insulin resistance in mice. J Clin Invest 2009;119:531-539.
15. Reilly MP, Lehrke M, Wolfe ML, Rohatgi A, Lazar MA, Rader DJ. Resistin is an inflammatory marker of atherosclerosis in humans. Circulation 2005;111:932-939. (Pubitemid 40279897)
16. Aromaa A, Koskinen S. Health and functional capacity in Finland. Baseline results of the Health 2000 Health Examination Survey. Publications of the National Public Health Institute; 2004, B12/2004.
17. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998;15: 539-553. (Pubitemid 28319935)
18. Balkau B, Charles MA. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med 1999;16: 442-443.
19. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-3421.
20. Zimmet P, Magliano D, Matsuzawa Y, Alberti G, Shaw J. The metabolic syndrome: a global public health problem and a new definition. J Atheroscler Thromb 2005;12: 295-300.
21. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC Jr, International Diabetes Federation Task Force on Epidemiology and Prevention, Hational Heart, Lung, and Blood Institute, American Heart Association, World Heart Federation, International Atherosclerosis Society and International Association for the Study of Obesity. Harmonizing the metabolic syndrome: A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009;120:1640-1645.
22. Sipila K, Koivistoinen T, Moilanen L, Nieminen T, Reunanen A, Jula A, Salomaa V, Kaaja R, Koobi T, Kukkonen-Harjula K, Majahalme S, Kahonen M. Metabolic syndrome and arterial stiffness: The Health 2000 Survey. Metabolism 2007;56: 320-326. (Pubitemid 46210215)
23. Kunnari AM, Savolainen ER, Ukkola OH, Kesaniemi YA, Jokela MA. The expression of human resistin in different leucocyte lineages is modulated by LPS and TNFalpha. Regul Pept 2009;157:57-63.
24. Aquilante CL, Kosmiski LA, Knutsen SD, Zineh I. Relationship between plasma resistin concentrations, inflammatory chemokines, and components of the metabolic syndrome in adults. Metabolism 2008;57:494-501. (Pubitemid 351317963)
25. Won JC, Park CY, Lee WY, Lee ES, Oh SW, Park SW. Association of plasma levels of resistin with subcutaneous fat mass and markers of inflammation but not with metabolic determinants or insulin resistance. J Korean Med Sci 2009; 24:695-700.
26. Stenholm S, Koster A, Alley DE, Visser M, Maggio M, Harris TB, Egan JM, Bandinelli S, Guralnik JM, Ferrucci L. Adipocytokines and the metabolic syndrome among older persons with and without obesity-the InCHIANTI Study. Clin Endocrinol (Oxf) 2010;73:55-65.
27. Norata GD, Ongari M, Garlaschelli K, Raselli S, Grigore L, Catapano AL. Plasma resistin levels correlate with determinants of the metabolic syndrome. Eur J Endocrinol 2007;156: 279-284. (Pubitemid 46554524)
28. Huang PL. A comprehensive definition for metabolic syndrome. Dis Model Mech 2009;2:231-237.
29. Qi Q, Wang J, Li H, Yu Z, Ye X, Hu FB, Franco OH, Pan A, Liu Y, Lin X. Associations of resistin with inflammatory and fibrinolytic markers, insulin resistance, and metabolic syndrome in middle-aged and older Chinese. Eur J Endocrinol 2008;159:585-593.
30. Youn BS, Yu KY, Park HJ, Lee NS, Min SS, Youn MY, Cho YM, Park YJ, Kim SY, Lee HK, Park KS. Plasma resistin concentrations measured by enzyme-linked immunosorbent assay using a newly developed monoclonal antibody are elevated in individuals with type 2 diabetes mellitus. J Clin Endocrinol Metab 2004;89:150-156. (Pubitemid 38183874)
31. Kaser S, Kaser A, Sandhofer A, Ebenbichler CF, Tilg H, Patsch JR. Resistin messenger-RNA expression is increased by proinflammatory cytokines in vitro. Biochem Biophys Res Commun 2003;309:286-290. (Pubitemid 37025889)
32. Kunnari A, Ukkola O, Paivansalo M, Kesaniemi YA. High plasma resistin level is associated with enhanced highly sensitive C-reactive protein and leukocytes. J Clin Endocrinol Metab 2006;91:2755-2760. (Pubitemid 44024647)
33. Pagano C, Soardo G, Pilon C, Milocco C, Basan L, Milan G, Donnini D, Faggian D, Mussap M, Plebani M, Avellini C, Federspil G, Sechi LA, Vettor R. Increased serum resistin in nonalcoholic fatty liver disease is related to liver disease severity and not to insulin resistance. J Clin Endocrinol Metab 2006;91:1081-1086. (Pubitemid 43357784)
34. Takata Y, Osawa H, Kurata M, Kurokawa M, Yamauchi J, Ochi M, Nishida W, Okura T, Higaki J, Makino H. Hyperresistinemia is associated with coexistence of hypertension and type 2 diabetes. Hypertension 2008;51: 534-539. (Pubitemid 351156444)